U.S. Markets close in 6 hrs 1 mins

Bionomics Limited (BNO.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.445-0.010 (-2.198%)
At close: 4:10PM AEST

Bionomics Limited

31 Dalgleish Street
Thebarton, SA 5031
61 8 8354 6100

Full Time Employees

Key Executives

Dr. Deborah Rathjen B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSECEO, MD & Exec. DirectorN/AN/A59
Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCISLegal Counsel and Company Sec.321.7kN/AN/A
Mr. Steve LydeamoreChief Financial OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials and Phase I multiple ascending dose trials for the treatment of generalized anxiety disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a novel compound to disrupt the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has collaboration agreement with Merck & Co. to develop compounds targeting cognitive impairment in conditions, such as ADHD, alzheimer’s disease, parkinson’s disease, and schizophrenia. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Corporate Governance

Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.